Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.42B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.99M
Average 1.35M
Returns on capital
Enliven Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-22.6%
avg 1.6%
ROIC
-26.0%
avg -49.4%
ROA
-21.8%
avg -42.3%
Analysis
ROA is currently the strongest return metric at -21.8% versus its period average of -42.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Samuel S. Kintz | Co-Founder & Head of Pipeline | USD 956.09K | 40 | — | — |
Helen Louise Collins | Chief Medical Officer | USD 726.42K | 63 | 25.00K | 0.04% |
Joseph Lyssikatos | Co-Founder & Research Fellow | USD 709.4K | 61 | — | — |
Richard A. Fair | CEO, President & Director | USD 672.66K | 57 | 0 | <0.01% |
Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | USD 667.89K | 37 | 38.00K | 0.06% |
Damiette Smit | Vice President of Clinical Development | — | — | — | — |
Anish Patel | Co-Founder & Chief Operating Officer | — | 45 | 20.00K | 0.03% |
Galya D. Blachman | Chief Legal Officer & Head of Business Development | — | 49 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 19, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
71
$76.19M
Net Transaction Value
−$76.19M
Net selling
Most Active
Collins Helen Louise
25 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 19, 26Oct 19, 2026 | Hohl Benjamin Direct | Sell | $231.5K$231,545.56 |
| Oct 19, 26Oct 19, 2026 | Collins Helen Louise Direct | Sell | $192.3K$192,342.00 |
| Oct 1, 26Oct 1, 2026 | Garland J. Scott Direct | Sell | $606.7K$606,719.10 |
| Sep 17, 26Sep 17, 2026 | Hohl Benjamin Direct | Sell | $176.9K$176,851.10 |
| Sep 17, 26Sep 17, 2026 | Hohl Benjamin Direct | Sell | $111.3K$111,270.47 |
| Sep 17, 26Sep 17, 2026 | Hohl Benjamin Direct | Sell | $14.9K$14,881.45 |
| Sep 17, 26Sep 17, 2026 | Collins Helen Louise Direct | Sell | $145.9K$145,890.98 |
| Sep 17, 26Sep 17, 2026 | Collins Helen Louise Direct | Sell | $93.5K$93,507.21 |
| Sep 17, 26Sep 17, 2026 | Collins Helen Louise Direct | Sell | $12.4K$12,355.68 |
| Aug 17, 26Aug 17, 2026 | Hohl Benjamin Direct | Sell | $270.2K$270,168.37 |
1–10 of 71
Summary
Insiders reported 0 buys worth $0.00 and 71 sells worth $76.19M over the last 12 months. That adds up to net selling of $76.19M. Collins Helen Louise was the most active insider with 25 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Enliven Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ELVN's management, answered from reported figures.
Who manages ELVN?
Enliven Therapeutics, Inc. (ELVN) lists 8 active executives. The top listed executive is Damiette Smit, Vice President of Clinical Development.
Are ELVN insiders buying or selling?
Recent insider activity shows net selling of $44.40M.
Continue the stock analysis
Jump to another research area for this company.